ExodusPoint Capital Management LP Purchases 133,268 Shares of Astrazeneca Plc $AZN

ExodusPoint Capital Management LP grew its position in shares of Astrazeneca Plc (NYSE:AZN) by 889.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 148,255 shares of the company’s stock after buying an additional 133,268 shares during the period. ExodusPoint Capital Management LP’s holdings in Astrazeneca were worth $26,019,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its position in shares of Astrazeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after purchasing an additional 2,789 shares during the period. AQR Capital Management LLC increased its position in shares of Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after purchasing an additional 11,690 shares during the period. Amundi increased its position in shares of Astrazeneca by 54.4% in the second quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after purchasing an additional 3,618 shares during the period. Jump Financial LLC increased its position in shares of Astrazeneca by 898.4% in the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after purchasing an additional 30,125 shares during the period. Finally, Daiwa Securities Group Inc. increased its position in shares of Astrazeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after purchasing an additional 559 shares during the period. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Astrazeneca in a research report on Monday, June 8th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Performance

NYSE:AZN opened at $178.79 on Wednesday. The stock’s 50-day simple moving average is $188.26 and its 200 day simple moving average is $186.16. The firm has a market capitalization of $277.29 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.54 and a beta of 0.25. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, analysts anticipate that Astrazeneca Plc will post 9.39 EPS for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.